リウマチ・膠原病内科抄読会: AURORA2 VCS併用マルチターゲットセラピーのループス腎炎における長期安全性について

概要

本スライドの対象者

参考文献

• Saxena A, Ginzler EM, Gibson K et al. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the Phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 2023 Jul 19.

• Hemmelgarn BR, Manns BJ, Lloyd A et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010 Feb 3;303(5):423-9.

• Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S):S1-S276.

• Fanouriakis A, Kostopoulou M, Cheema K et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.

• Allen ME, Rus V, Szeto GL. Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. Trends Mol Med. 2021 Feb;27(2):152-171.

• Mok CC. Best Pract Res Clin Rheumatol. 2017 Jun;31(3):429-438.

• Liao R et al. PLoS One. 2015 Jul 10;10(7):e0132724.

• van Gelder T, Lerma E, Engelke K et al. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. Expert Rev Clin Pharmacol. 2022 May;15(5):515-529.

• Kolic J, Beet L, Overby P et al. Differential Effects of Voclosporin and Tacrolimus on Insulin Secretion From Human Islets. Endocrinology. 2020 Nov 1;161(11):bqaa162.

• 天崎 吉晴, カルシニューリン・NFAT系とその阻害薬, 日本臨床免疫学会会誌, 2010, 33 巻, 5 号, p. 249-261

• 日本リウマチ学会編:全身性エリテマトーデス診療ガイドライン2019

• Hahn BH et al. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808.

• Zhonghua et al. CCR 2020 Mar 1;59(3):172-185. Chinese.

• Chi Chiu Mok et al. The Lancet Rheumatology. VOLUME 3, ISSUE 7, E517-E531, JULY 01, 2021

• Ponticelli C, Podestà MA. Calcineurin inhibitors in lupus nephritis. J Nephrol. 2021 Apr;34(2):399-402.

• Van Gelder T, Huizinga RB, Noukens J, et al. Use of therapeutic drug monitoring does not add clinical value for voclosporin in patients with lupus nephritis. J Am Soc Nephrol. 2020;31:594.

• Heo YA. Voclosporin: First Approval. Drugs. 2021 Apr;81(5):605-610.

• Rovin BH, Solomons N, Pendergraft WF 3rd et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019 Jan;95(1):219-231

• Rovin BH, Teng YKO, Ginzler EM et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070-2080.

• Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004 Feb;65(2):521-30.

• Fanouriakis A, Kostopoulou M, Alunno A et al.. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun;78(6):736-745.

• Rojas-Rivera JE, García-Carro C, Ávila AI et al. Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Clin Kidney J. 2023 Mar 22;16(9):1384-1402.

• Petri M et al. N Engl J Med. 2005 Dec 15;353(24):2550-8.

• Ogando NS, Metscher E, Moes DJAR et al.The Cyclophilin-Dependent Calcineurin Inhibitor Voclosporin Inhibits SARS-CoV-2 Replication in Cell Culture. Transpl Int. 2022 Jun 24;35:10369.

• Arends, E. J., S. Meziyerh, D. J. Moes, S et al. "Antiviral Effects of Voclosporin on SARS-CoV-2 in Immunocompromised Kidney Patients." Journal of the American Society of Nephrology (2022): 328-329.

• Moroni G, Gatto M, Tamborini F et al. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis. 2020 Aug;79(8):1077-1083.